Literature DB >> 28057699

Glucagon-Like Peptide 1 and Its Analogs Act in the Dorsal Raphe and Modulate Central Serotonin to Reduce Appetite and Body Weight.

Rozita H Anderberg1, Jennifer E Richard1, Kim Eerola1, Lorena López-Ferreras1, Elin Banke1, Caroline Hansson1, Hans Nissbrandt2, Filip Berqquist2, Fiona M Gribble3, Frank Reimann3, Ingrid Wernstedt Asterholm1, Christophe M Lamy4, Karolina P Skibicka5.   

Abstract

Glucagon-like peptide 1 (GLP-1) and serotonin play critical roles in energy balance regulation. Both systems are exploited clinically as antiobesity strategies. Surprisingly, whether they interact in order to regulate energy balance is poorly understood. Here we investigated mechanisms by which GLP-1 and serotonin interact at the level of the central nervous system. Serotonin depletion impaired the ability of exendin-4, a clinically used GLP-1 analog, to reduce body weight in rats, suggesting that serotonin is a critical mediator of the energy balance impact of GLP-1 receptor (GLP-1R) activation. Serotonin turnover and expression of 5-hydroxytryptamine (5-HT) 2A (5-HT2A) and 5-HT2C serotonin receptors in the hypothalamus were altered by GLP-1R activation. We demonstrate that the 5-HT2A, but surprisingly not the 5-HT2C, receptor is critical for weight loss, anorexia, and fat mass reduction induced by central GLP-1R activation. Importantly, central 5-HT2A receptors are also required for peripherally injected liraglutide to reduce feeding and weight. Dorsal raphe (DR) harbors cell bodies of serotonin-producing neurons that supply serotonin to the hypothalamic nuclei. We show that GLP-1R stimulation in DR is sufficient to induce hypophagia and increase the electrical activity of the DR serotonin neurons. Finally, our results disassociate brain metabolic and emotionality pathways impacted by GLP-1R activation. This study identifies serotonin as a new critical neural substrate for GLP-1 impact on energy homeostasis and expands the current map of brain areas impacted by GLP-1R activation.
© 2017 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28057699      PMCID: PMC6237271          DOI: 10.2337/db16-0755

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  54 in total

1.  Differential effects of p-chlorophenylalanine and 5,7-dihydroxytryptamine on feeding in rats.

Authors:  B G Hoebel; F P Zemlan; M E Trulson; R G MacKenzie; R P DuCret; C Norelli
Journal:  Ann N Y Acad Sci       Date:  1978-06-12       Impact factor: 5.691

2.  The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test.

Authors:  Ruben Isacson; Elisabet Nielsen; Karin Dannaeus; Göran Bertilsson; Cesare Patrone; Olof Zachrisson; Lilian Wikström
Journal:  Eur J Pharmacol       Date:  2010-10-14       Impact factor: 4.432

3.  Hyperphagia and increased growth in rats after intraventricular injection of 5,7-dihydroxytryptamine.

Authors:  C F Saller; E M Stricker
Journal:  Science       Date:  1976-04-23       Impact factor: 47.728

4.  The acute anorexic effect of liraglutide, a GLP-1 receptor agonist, does not require functional leptin receptor, serotonin, and hypothalamic POMC and CART activities in mice.

Authors:  Katsunori Nonogaki; Takao Kaji
Journal:  Diabetes Res Clin Pract       Date:  2016-08-26       Impact factor: 5.602

5.  GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality.

Authors:  Rozita H Anderberg; Jennifer E Richard; Caroline Hansson; Hans Nissbrandt; Filip Bergquist; Karolina P Skibicka
Journal:  Psychoneuroendocrinology       Date:  2015-12-17       Impact factor: 4.905

6.  Pharmacological, but not genetic, disruptions in 5-HT(2C) receptor function attenuate LPS anorexia in mice.

Authors:  Lori Asarian; Brigitte S Kopf; Nori Geary; Wolfgang Langhans
Journal:  Pharmacol Biochem Behav       Date:  2007-01-18       Impact factor: 3.533

7.  Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6.

Authors:  Rozita Shirazi; Vilborg Palsdottir; Jim Collander; Fredrik Anesten; Heike Vogel; Fanny Langlet; Alexander Jaschke; Annette Schürmann; Vincent Prévot; Ruijin Shao; John-Olov Jansson; Karolina Patrycja Skibicka
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-18       Impact factor: 11.205

8.  Glucagon-like peptide 1 (7-36) amide (GLP-1) and exendin-4 stimulate serotonin release in rat hypothalamus.

Authors:  Luigi Brunetti; Giustino Orlando; Lucia Recinella; Sheila Leone; Claudio Ferrante; Annalisa Chiavaroli; Francesco Lazzarin; Michele Vacca
Journal:  Peptides       Date:  2008-04-20       Impact factor: 3.750

9.  Serotonin mediates CA1 spine density but is not crucial for ovarian steroid regulation of synaptic plasticity in the adult rat dorsal hippocampus.

Authors:  Stephen E Alves; Elena Hoskin; Susan J Lee; Wayne G Brake; Deveroux Ferguson; Victoria Luine; Patrick B Allen; Paul Greengard; Bruce S McEwen
Journal:  Synapse       Date:  2002-08       Impact factor: 2.562

10.  Pharmacological stimulation of serotonin 5-HT1B receptors enhances increases in plasma active glucagon-like peptide-1 levels induced by dipeptidyl peptidase-4 inhibition independently of feeding in mice.

Authors:  K Nonogaki; T Kaji
Journal:  Diabetes Metab       Date:  2015-07-30       Impact factor: 6.041

View more
  20 in total

1.  Obesity: 5-HT2A in GLP1-mediated weight loss.

Authors:  Alan Morris
Journal:  Nat Rev Endocrinol       Date:  2017-01-30       Impact factor: 43.330

Review 2.  The possible factors affecting microglial activation in cases of obesity with cognitive dysfunction.

Authors:  Titikorn Chunchai; Nipon Chattipakorn; Siriporn C Chattipakorn
Journal:  Metab Brain Dis       Date:  2017-11-21       Impact factor: 3.584

Review 3.  Targeting dysfunctional beta-cell signaling for the potential treatment of type 1 diabetes mellitus.

Authors:  Rachel J Fenske; Michelle E Kimple
Journal:  Exp Biol Med (Maywood)       Date:  2018-03-04

Review 4.  GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight.

Authors:  Giulia Monti; Diana Gomes Moreira; Mette Richner; Henricus Antonius Maria Mutsaers; Nelson Ferreira; Asad Jan
Journal:  Cells       Date:  2022-06-25       Impact factor: 7.666

5.  Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes.

Authors:  Alfonso Galderisi; Jennifer Sherr; Michelle VanName; Lori Carria; Melinda Zgorski; Eileen Tichy; Kate Weyman; Eda Cengiz; Stuart Weinzimer; William Tamborlane
Journal:  J Clin Endocrinol Metab       Date:  2018-03-01       Impact factor: 5.958

Review 6.  Brain-gut-microbiome interactions in obesity and food addiction.

Authors:  Arpana Gupta; Vadim Osadchiy; Emeran A Mayer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-08-27       Impact factor: 46.802

7.  Hyperhomocysteinemia influenced malnutrition in Parkinson's disease patients.

Authors:  Svetlana Tomic; Vlasta Pekic; Zeljka Popijac; Tomislav Pucic; Marta Petek Vinkovic; Tihana Gilman Kuric; Zvonimir Popovic
Journal:  Neurol Sci       Date:  2018-06-30       Impact factor: 3.307

8.  TPH2 in the Dorsal Raphe Nuclei Regulates Energy Balance in a Sex-Dependent Manner.

Authors:  Hailan Liu; Chunmei Wang; Meng Yu; Yongjie Yang; Yang He; Hesong Liu; Chen Liang; Longlong Tu; Nan Zhang; Lina Wang; Julia Wang; Feng Liu; Fang Hu; Yong Xu
Journal:  Endocrinology       Date:  2021-01-01       Impact factor: 4.736

Review 9.  The diverse effects of brain glucagon-like peptide 1 receptors on ingestive behaviour.

Authors:  Diana L Williams
Journal:  Br J Pharmacol       Date:  2021-06-18       Impact factor: 8.739

10.  The ketogenic diet is not feasible as a therapy in a CD-1 nu/nu mouse model of renal cell carcinoma with features of Stauffer's syndrome.

Authors:  Silvia Vidali; Sepideh Aminzadeh-Gohari; René Günther Feichtinger; Renaud Vatrinet; Andreas Koller; Felix Locker; Tricia Rutherford; Maura O'Donnell; Andrea Stöger-Kleiber; Bridget Lambert; Thomas Klaus Felder; Wolfgang Sperl; Barbara Kofler
Journal:  Oncotarget       Date:  2017-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.